Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL GETZ

Allopathic & Osteopathic Physicians Dermatology

NPI
1508866443
CMS profile
249750
Location
WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$888.03

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $874.03 31
Education $14.00 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL GETZ

NPI 1508866443 · CMS profile ID 249750

Allopathic & Osteopathic Physicians / Dermatology

WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508866443?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508866443?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508866443?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
PAUL GETZ, NPI 1508866443, CMS profile ID 249750, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1508866443?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $888.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $116.6612/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335855 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.7412/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621183 CMS
UCB, Inc. $25.5711/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021481529 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.5711/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621181 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $144.7011/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621185 CMS
Dermavant Sciences, Inc. $179.5610/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991189689 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $7.3009/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621179 CMS
ABBVIE INC. $6.8009/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335853 CMS
PFIZER INC. $10.4008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050336871 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.7008/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621177 CMS
UCB, Inc. $18.1407/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021481525 CMS
ABBVIE INC. $6.2607/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335851 CMS
E.R. Squibb & Sons, L.L.C. $16.2807/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014922173 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.2707/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621175 CMS
ABBVIE INC. $5.7006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335849 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $5.7906/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621173 CMS
E.R. Squibb & Sons, L.L.C. $16.2805/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014922017 CMS
PFIZER INC. $3.3204/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049500346 CMS
E.R. Squibb & Sons, L.L.C. $13.0204/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014922009 CMS
PFIZER INC. $5.4604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049667407 CMS
PFIZER INC. $5.8703/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049692825 CMS
ABBVIE INC. $6.5003/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335847 CMS
ABBVIE INC. $129.7303/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335845 CMS
PFIZER INC. $3.8503/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049408289 CMS
ABBVIE INC. $30.4103/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335843 CMS
Dermavant Sciences, Inc. $7.2403/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991189685 CMS
PFIZER INC. $5.2503/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049755529 CMS
Organogenesis Inc. $28.4802/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048146887 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.5602/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997131579 CMS
Incyte Corporation $16.1202/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044851523 CMS
ABBVIE INC. $7.5002/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335841 CMS
Dermavant Sciences, Inc. $14.0001/26/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991189681 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,203.48 19
PY2020 $161.56 8
PY2021 $1,512.52 60
PY2022 $1,032.69 42
PY2023 $888.03 32
PY2024 $985.47 43
PY2025 $621.06 48

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,013.60 1
PY2025 Principal investigator $446,834.92 130
PY2024 Recipient $7,087.86 1
PY2024 Principal investigator $650,362.14 156
PY2023 Recipient $10,934.40 2
PY2023 Principal investigator $209,903.19 44
PY2022 Principal investigator $139,606.12 29
PY2021 Recipient $11,617.83 3
PY2021 Principal investigator $358,649.13 52
PY2020 Principal investigator $277,127.30 39
PY2019 Principal investigator $329,491.24 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

157 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,850.00 12/19/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079001530
Principal investigator 1 Incyte Corporation $1,926.00 12/17/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692869
Principal investigator 1 Incyte Corporation $2,320.20 12/12/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692871
Principal investigator 1 Janssen Research & Development, LLC $1,453.00 12/12/2024 Non-covered Recipient Entity
Dr. Paul Getz
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962801
Principal investigator 1 Incyte Corporation $2,047.00 12/11/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692883
Principal investigator 1 Incyte Corporation $2,693.00 12/11/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692885
Principal investigator 1 Incyte Corporation $1,233.30 12/11/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692911
Principal investigator 1 Janssen Research & Development, LLC $2,154.00 12/09/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079001550
Principal investigator 1 PFIZER INC. $18,000.00 12/04/2024 Non-covered Recipient Entity
Paul Getz MD SC dba Dundee Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1130967876
Principal investigator 1 Incyte Corporation $49.40 12/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692887
Principal investigator 1 Incyte Corporation $32.40 12/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692889
Principal investigator 1 Incyte Corporation $0.60 12/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692891
Principal investigator 1 Incyte Corporation $45.80 12/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692901
Principal investigator 1 Janssen Research & Development, LLC $2,253.00 12/02/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079001554
Principal investigator 1 Incyte Corporation $1,743.30 11/26/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692867
Principal investigator 1 Incyte Corporation $10,661.40 11/07/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692731
Principal investigator 1 Incyte Corporation $1,412.90 11/06/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692873
Principal investigator 1 Incyte Corporation $2,944.00 11/06/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692875
Principal investigator 1 Janssen Research & Development, LLC $2,882.00 11/01/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079001548
Principal investigator 1 Janssen Research & Development, LLC $2,970.00 10/28/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079001524
Principal investigator 1 Incyte Corporation $42.00 10/22/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692925
Principal investigator 1 Incyte Corporation $1,926.00 10/22/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692957
Principal investigator 1 Incyte Corporation $22.00 10/22/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692959
Principal investigator 1 Incyte Corporation $58.00 10/22/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692961
Principal investigator 1 Incyte Corporation $2,047.00 10/11/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692877
Principal investigator 1 Incyte Corporation $703.60 10/11/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692879
Principal investigator 1 Incyte Corporation $2,811.00 10/11/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692881
Principal investigator 1 Incyte Corporation $2,009.00 10/11/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692903
Principal investigator 1 Incyte Corporation $3,170.00 10/11/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692963
Principal investigator 1 Janssen Research & Development, LLC $1,904.00 10/03/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079001540
Principal investigator 1 Janssen Research & Development, LLC $2,145.00 09/30/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079001526
Principal investigator 1 Incyte Corporation $8,462.70 09/24/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692955
Principal investigator 1 PFIZER INC. $2,500.00 09/24/2024 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131015036
Principal investigator 1 Incyte Corporation $1,881.00 09/18/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692859
Principal investigator 1 Janssen Research & Development, LLC $4,732.00 09/18/2024 Non-covered Recipient Entity
Dr. Paul Getz
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962799
Principal investigator 1 Janssen Research & Development, LLC $5,659.00 09/02/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079001532
Principal investigator 1 Incyte Corporation $2,244.60 08/27/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692851
Principal investigator 1 Janssen Research & Development, LLC $5,265.00 08/26/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079001556
Principal investigator 1 Incyte Corporation $3,086.10 08/22/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692853
Principal investigator 1 Incyte Corporation $1,808.10 08/14/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692895
Principal investigator 1 Incyte Corporation $3,359.70 08/01/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692849
Principal investigator 1 PFIZER INC. $2,132.00 08/01/2024 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131015609
Principal investigator 1 Janssen Research & Development, LLC $2,954.00 07/22/2024 Non-covered Recipient Entity
Dr. Paul Getz
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962795
Principal investigator 1 Eli Lilly and Company $2,583.00 07/11/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1137364477
Principal investigator 1 Incyte Corporation $7,466.00 07/11/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134692953
Principal investigator 1 Incyte Corporation $2,944.00 07/10/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692855
Principal investigator 1 Incyte Corporation $1,547.90 07/10/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692857
Principal investigator 1 Incyte Corporation $53.46 07/05/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692861
Principal investigator 1 Incyte Corporation $65.76 07/05/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692863
Principal investigator 1 Incyte Corporation $65.76 07/05/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692865
Principal investigator 1 Incyte Corporation $65.76 07/05/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692937
Principal investigator 1 Incyte Corporation $65.76 07/05/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692939
Principal investigator 1 Janssen Research & Development, LLC $5,669.00 06/28/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079001542
Principal investigator 1 PFIZER INC. $690.00 06/28/2024 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131054884
Principal investigator 1 Janssen Research & Development, LLC $2,077.00 06/27/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079001528
Principal investigator 1 Amgen Inc. $31,363.00 06/25/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309179
Principal investigator 1 PFIZER INC. $2,132.00 06/25/2024 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131054958
Principal investigator 1 Incyte Corporation $1,247.20 06/07/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692829
Principal investigator 1 Incyte Corporation $1,908.00 06/07/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692835
Principal investigator 1 Incyte Corporation $2,693.00 06/07/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692897
Principal investigator 1 Janssen Research & Development, LLC $4,285.00 06/03/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079001538
Principal investigator 1 Amgen Inc. $23,170.00 05/23/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
IGNITE P3 AD Adult Monotherapy Study 1 No dispute reported 06/30/2026 1096310981
Principal investigator 1 Janssen Research & Development, LLC $1,453.00 05/10/2024 Non-covered Recipient Entity
Dr. Paul Getz
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962797
Principal investigator 1 Incyte Corporation $2,047.00 05/03/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692825
Principal investigator 1 Incyte Corporation $2,009.00 05/03/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692827
Principal investigator 1 Incyte Corporation $2,124.30 05/03/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692831
Principal investigator 1 Incyte Corporation $124.54 05/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692845
Principal investigator 1 Incyte Corporation $29.16 05/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692847
Principal investigator 1 Janssen Research & Development, LLC $5,756.00 05/02/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079001546
Principal investigator 1 Janssen Research & Development, LLC $5,962.00 04/29/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079001544
Principal investigator 1 Janssen Research & Development, LLC $5,073.00 04/26/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079001558
Recipient E.R. Squibb & Sons, L.L.C. $7,087.86 04/19/2024 Covered Recipient Physician Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1123481994
Principal investigator 1 Janssen Research & Development, LLC $2,195.00 04/19/2024 Non-covered Recipient Entity
Dr. Paul Getz
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962805
Principal investigator 1 Incyte Corporation $2,853.00 04/05/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692833
Principal investigator 1 PFIZER INC. $2,132.00 04/04/2024 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131092315
Principal investigator 1 Incyte Corporation $226.52 04/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692837
Principal investigator 1 Incyte Corporation $54.76 04/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692839
Principal investigator 1 Incyte Corporation $197.44 04/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692841
Principal investigator 1 Incyte Corporation $183.20 04/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692843
Principal investigator 1 Incyte Corporation $6.82 04/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692905
Principal investigator 1 Amgen Inc. $6,877.32 03/26/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309181
Principal investigator 1 Janssen Research & Development, LLC $5,424.00 03/25/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079001552
Principal investigator 1 Janssen Research & Development, LLC $10,942.00 03/18/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079001534
Principal investigator 1 Incyte Corporation $2,009.00 03/13/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692785
Principal investigator 1 Incyte Corporation $2,047.00 03/13/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692793
Principal investigator 1 Incyte Corporation $2,153.00 03/13/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692795
Principal investigator 1 Incyte Corporation $2,944.00 03/13/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692797
Principal investigator 1 Incyte Corporation $16.44 03/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692745
Principal investigator 1 Incyte Corporation $62.27 03/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692769
Principal investigator 1 Incyte Corporation $16.44 03/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692809
Principal investigator 1 Incyte Corporation $2.43 03/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692893
Principal investigator 1 Incyte Corporation $14.58 03/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692907
Principal investigator 1 Incyte Corporation $16.44 03/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692933
Principal investigator 1 Incyte Corporation $16.44 03/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692935
Principal investigator 1 Janssen Research & Development, LLC $5,518.00 02/22/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079001536
Principal investigator 1 Incyte Corporation $1,707.30 02/07/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692799
Principal investigator 1 Incyte Corporation $22.90 02/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692743
Principal investigator 1 Incyte Corporation $54.76 02/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692749
Principal investigator 1 Incyte Corporation $49.36 02/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692753
Principal investigator 1 Incyte Corporation $64.72 02/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692763
Principal investigator 1 Incyte Corporation $1.86 02/02/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692899
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,617.76 02/01/2024 Non-covered Recipient Entity
PAUL GETZ MD SC DUNDEE DERMATOLOGY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1089696521
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,275.88 01/26/2024 Non-covered Recipient Entity
Dundee Dermatology
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 1123477098
Principal investigator 1 Eli Lilly and Company $215.00 01/25/2024 Non-covered Recipient Entity
PAUL GETZ MD SC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1137364723
Principal investigator 1 Janssen Research & Development, LLC $3,719.00 01/25/2024 Non-covered Recipient Entity
Dr. Paul Getz
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962807
Principal investigator 1 Novartis Pharmaceuticals Corporation $332,525.01 01/15/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1089686673
Principal investigator 1 Incyte Corporation $1,808.10 01/08/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692791
Principal investigator 1 Janssen Research & Development, LLC $2,195.00 01/05/2024 Non-covered Recipient Entity
Dr. Paul Getz
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962803
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692733
Principal investigator 1 Incyte Corporation $8.06 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692735
Principal investigator 1 Incyte Corporation $12.15 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692737
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692739
Principal investigator 1 Incyte Corporation $19.44 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692741
Principal investigator 1 Incyte Corporation $38.88 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692747
Principal investigator 1 Incyte Corporation $49.36 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692751
Principal investigator 1 Incyte Corporation $48.60 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692755
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692757
Principal investigator 1 Incyte Corporation $57.25 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692759
Principal investigator 1 Incyte Corporation $64.72 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692761
Principal investigator 1 Incyte Corporation $59.13 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692765
Principal investigator 1 Incyte Corporation $65.76 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692767
Principal investigator 1 Incyte Corporation $123.40 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692771
Principal investigator 1 Incyte Corporation $135.40 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692773
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692775
Principal investigator 1 Incyte Corporation $68.70 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692777
Principal investigator 1 Incyte Corporation $80.90 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692779
Principal investigator 1 Incyte Corporation $145.62 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692781
Principal investigator 1 Incyte Corporation $246.80 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692783
Principal investigator 1 Incyte Corporation $226.52 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692787
Principal investigator 1 Incyte Corporation $197.44 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692789
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692801
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692803
Principal investigator 1 Incyte Corporation $2.48 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692805
Principal investigator 1 Incyte Corporation $12.15 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692807
Principal investigator 1 Incyte Corporation $49.36 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692811
Principal investigator 1 Incyte Corporation $64.72 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692813
Principal investigator 1 Incyte Corporation $48.60 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692815
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692817
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692819
Principal investigator 1 Incyte Corporation $68.70 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692821
Principal investigator 1 Incyte Corporation $65.76 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692823
Principal investigator 1 Incyte Corporation $54.76 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692909
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692913
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692915
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692917
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692919
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692921
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692923
Principal investigator 1 Incyte Corporation $91.60 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692927
Principal investigator 1 Incyte Corporation $62.27 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692929
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692931
Principal investigator 1 Incyte Corporation $65.76 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692941
Principal investigator 1 Incyte Corporation $65.76 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692943
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692945
Principal investigator 1 Incyte Corporation $4.65 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692947
Principal investigator 1 Incyte Corporation $2.48 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692949
Principal investigator 1 Incyte Corporation $2.79 01/04/2024 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134692951